Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Double-Blind, Multiple-Dose Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Between IDX320 and IDX184 in Healthy Subjects

Next Previous
Trial Profile

A Phase I, Double-Blind, Multiple-Dose Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Between IDX320 and IDX184 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IDX 184 (Primary) ; IDX 320 (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme

Most Recent Events

  • 16 Aug 2012 The US FDA has placed a partial clinical hold on IDX 184, according to a Idenix Pharmaceuticals media release.
  • 07 Sep 2010 Full data will be presented at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) 2010, according to an Idenix media release.
  • 07 Sep 2010 Status changed from recruiting to completed, according to an Idenix media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top